-
The detrimental effect of biopsy preceding resection in surgically accessible glioblastoma: results from the national cancer database J Neurooncol. (IF 3.9) Pub Date : 2024-03-16
Abstract Purpose Aggressive resection in surgically-accessible glioblastoma (GBM) correlates with improved survival over less extensive resections. However, the clinical impact of performing a biopsy before definitive resection have not been previously evaluated. Methods We analyzed 17,334 GBM patients from the NCDB from 2010–2014. We categorized them into: “upfront resection” and “biopsy followed
-
Effects of cognitive-motor intervention for pediatric posterior fossa tumor survivors: results of a pilot study J Neurooncol. (IF 3.9) Pub Date : 2024-03-15 Vladimir N. Kasatkin, Elizaveta N. Romanova, Elena V. Glebova, Alena A. Deviaterikova, Vera V. Tolchennikova, Anastasia A. Sharapkova, Piruza A. Manukyan, Nadezhda M. Karpova, Roza A. Sarkisyan, Alexander F. Karelin
-
The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study J Neurooncol. (IF 3.9) Pub Date : 2024-03-08 Vincenzo Di Nunno, Giuseppe Lombardi, Matteo Simonelli, Giuseppe Minniti, Angela Mastronuzzi, Valentina Di Ruscio, Martina Corrà, Marta Padovan, Marta Maccari, Mario Caccese, Giorgia Simonetti, Arianna Berlendis, Mariangela Farinotti, Bianca Pollo, Manila Antonelli, Antonio Di Muzio, Angelo Dipasquale, Sofia Asioli, Dario De Biase, Alicia Tosoni, Antonio Silvani, Enrico Franceschi
-
Fractionated stereotactic radiotherapy in craniopharyngiomas: A systematic review and single arm meta-analysis J Neurooncol. (IF 3.9) Pub Date : 2024-03-08 Lucca B. Palavani, Guilherme Melo Silva, Pedro G. L. B. Borges, Márcio Yuri Ferreira, Marcelo Porto Sousa, Marianna G. H. S. J. Leite, Leonardo de Barros Oliveira, Sávio Batista, Raphael Bertani, Allan Dias Polverini, André Beer-Furlan, Wellingson Paiva
-
Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis J Neurooncol. (IF 3.9) Pub Date : 2024-03-07 Thomas Graillon, Betty Salgues, Tatiana Horowitz, Laetitia Padovani, Romain Appay, Emeline Tabouret, Eric Guedj, Olivier Chinot
-
Inhibition of BMP signaling pathway induced senescence and calcification in anaplastic meningioma J Neurooncol. (IF 3.9) Pub Date : 2024-03-06 Kiyotaka Yokogami, Takashi Watanabe, Shinji Yamashita, Asako Mizuguchi, Hideo Takeshima
-
Impact of trametinib on the neuropsychological profile of NF1 patients J Neurooncol. (IF 3.9) Pub Date : 2024-03-05 Eve Lalancette, Édith Cantin, Marie-Ève Routhier, Chantal Mailloux, Marie-Claude Bertrand, Dorsa Sadat Kiaei, Valérie Larouche, Uri Tabori, Cynthia Hawkins, Benjamin Ellezam, Jean-Claude Décarie, Yves Théoret, Marie-Élaine Métras, Tara McKeown, Luis H. Ospina, Stéphanie Vairy, Vijay Ramaswamy, Hallie Coltin, Serge Sultan, Geneviève Legault, Éric Bouffet, Lucie Lafay-Cousin, Juliette Hukin, Craig Erker
-
Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1 J Neurooncol. (IF 3.9) Pub Date : 2024-03-05
Abstract Purpose Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder which commonly causes neoplasms leading to disfigurement or dysfunction. Mitogen-activated protein kinase inhibitors (MEKi) are generally well-tolerated treatments which target neural tumor progression in patients with NF1. However, cutaneous adverse events (CAEs) are common and may hinder patients’ abilities to remain
-
Prognostic value of cerebrospinal fluid tumor cell count in leptomeningeal disease from solid tumors J Neurooncol. (IF 3.9) Pub Date : 2024-03-05 Andrew B. Barbour, Barbara Blouw, Lynne P. Taylor, Jerome J. Graber, Tresa McGranahan, Molly Blau, Lia M. Halasz, Simon S. Lo, Yolanda D. Tseng, Vyshak Venur, Jonathan T. Yang
-
Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly J Neurooncol. (IF 3.9) Pub Date : 2024-03-05
Abstract Purpose Predicting resistance to first-generation Somatostatin Receptor Ligands (fg-SRL) in Acromegaly patients remains an ongong challenge. Tumor-associated immune components participate in various pathological processes, including drug-resistance. We aimed to identify the immune components involved in resistance of fg-SRL, and to investigate biomarkers that can be targeted to treat those
-
Preoperative patient-reported physical health-related quality of life predicts short-term postoperative outcomes in brain tumor patients J Neurooncol. (IF 3.9) Pub Date : 2024-03-04 Sachiv Chakravarti, Cathleen C. Kuo, Foad Kazemi, Ashley Kang, Calixto-Hope Lucas, Victoria Croog, David Kamson, Karisa C. Shreck, Matthias Holdhoff, Chetan Bettegowda, Debraj Mukherjee
-
Clinical presentation and extent of resection impacts progression-free survival in spinal ependymomas J Neurooncol. (IF 3.9) Pub Date : 2024-03-04 Mark A. Davison, Daniel T. Lilly, Arpan A. Patel, Ahmed Kashkoush, Xiaoying Chen, Wei Wei, Edward C. Benzel, Richard A. Prayson, Samuel Chao, Lilyana Angelov
-
Clinical characteristics and predictive factors of delayed diagnosis in patients with sellar germ cell tumors J Neurooncol. (IF 3.9) Pub Date : 2024-03-04
Abstract Purpose To investigate the clinical characteristics and predictive factors associated with delayed diagnosis in patients with sellar germ cell tumors (GCTs), aiming for early diagnosis. Methods A total of 345 patients with sellar GCTs were retrospectively collected. Patients were classified into a delayed diagnosis group (> 6 months from onset to diagnosis) and a non-delayed diagnosis group
-
Effect of sarcopenia and frailty on outcomes among patients with brain metastases J Neurooncol. (IF 3.9) Pub Date : 2024-03-02 Mervyn Jun Rui Lim, Zheting Zhang, Yilong Zheng, Ivan Wei Loon Khoo, Rhianne Caitlin Vaz Xin Ying, Sophie Jia Qian Koh, Ethanyn Lim, Pei Ing Ngam, Betsy Soon, Ying Liang Low, Li Feng Tan, Kejia Teo, Vincent Diong Weng Nga, Tseng Tsai Yeo
-
Prognostic impact of clinical and radiological factors on leptomeningeal metastasis from solid cancers J Neurooncol. (IF 3.9) Pub Date : 2024-03-02 Kanji Nakagawa, Koji Takano, Kazumi Nishino, Shuichi Ohe, Takahiro Nakayama, Hideyuki Arita
-
Midline invasion predicts poor prognosis in diffuse hemispheric glioma, H3 G34-mutant: an individual participant data review J Neurooncol. (IF 3.9) Pub Date : 2024-03-01 Yasuhito Kegoya, Yoshihiro Otani, Yohei Inoue, Ryo Mizuta, Fumiyo Higaki, Kana Washio, Shinichiro Koizumi, Kazuhiko Kurozumi, Joji Ishida, Kentaro Fujii, Norio Yamamoto, Yoshihiro Tanaka, Isao Date
-
Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors J Neurooncol. (IF 3.9) Pub Date : 2024-03-01 James L. Rogers, Thomas Wall, Alvina A. Acquaye-Mallory, Lisa Boris, Yeonju Kim, Kenneth Aldape, Martha M. Quezado, John A. Butman, James G. Smirniotopoulos, Huma Chaudhry, Christina I. Tsien, Prashant Chittiboina, Kareem Zaghloul, Orwa Aboud, Nicholas G. Avgeropoulos, Eric C. Burton, David M. Cachia, Karan S. Dixit, Jan Drappatz, Erin M. Dunbar, Peter Forsyth, Edina Komlodi-Pasztor, Jacob Mandel,
Purpose Multidisciplinary tumor boards (MTBs) integrate clinical, molecular, and radiological information and facilitate coordination of neuro-oncology care. During the COVID-19 pandemic, our MTB transitioned to a virtual and multi-institutional format. We hypothesized that this expansion would allow expert review of challenging neuro-oncology cases and contribute to the care of patients with limited
-
CPLX2 is a novel tumor suppressor and improves the prognosis in glioma J Neurooncol. (IF 3.9) Pub Date : 2024-03-01 Yuanbing Chen, Jieling Ning, Long Shu, Lingzhi Wen, Bokang Yan, Zuli Wang, Junhong Hu, Xiaokun Zhou, Yongguang Tao, Xuewei Xia, Jun Huang
-
The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study J Neurooncol. (IF 3.9) Pub Date : 2024-02-29
Abstract Purpose Currently, there remains a scarcity of established preoperative tests to accurately predict the isocitrate dehydrogenase (IDH) mutation status in clinical scenarios, with limited research has explored the potential synergistic diagnostic performance among metabolite, perfusion, and diffusion parameters. To address this issue, we aimed to develop an imaging protocol that integrated
-
Non-navigated 2D intraoperative ultrasound: An unsophisticated surgical tool to achieve high standards of care in glioma surgery J Neurooncol. (IF 3.9) Pub Date : 2024-02-28 Santiago Cepeda, Sergio García-García, Ignacio Arrese, Rosario Sarabia
-
Diverse learners: learning disabilities and quality of life following mind–body and health education interventions for adults with neurofibromatosis J Neurooncol. (IF 3.9) Pub Date : 2024-02-27
Abstract Purpose Neurofibromatosis (NF) is associated with low quality-of-life (QoL). Learning disabilities are prevalent among those with NF, further worsening QoL and potentially impacting benefits from mind–body and educational interventions, yet research on this population is scarce. Here, we address this gap by comparing NF patients with and without learning disabilities on QoL at baseline and
-
Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years’ experience of a single center J Neurooncol. (IF 3.9) Pub Date : 2024-02-22 Melek Tugce Yilmaz, Alper Kahvecioglu, Gozde Yazici, Sepideh Mohammadipour, Neyran Kertmen, Gokcen Coban Cifci, Faruk Zorlu
-
Prognostic factors analysis of diffuse midline glioma J Neurooncol. (IF 3.9) Pub Date : 2024-02-21 Jing Jiang, Wen-bin Li, Shao-wen Xiao
-
Validation of a methylation-based signature for subventricular zone involvement in glioblastoma J Neurooncol. (IF 3.9) Pub Date : 2024-02-20 Felix Ehret, Oliver Zühlke, Leonille Schweizer, Johannes Kahn, Christoph Csapo-Schmidt, Siyer Roohani, Daniel Zips, David Capper, Sebastian Adeberg, Amir Abdollahi, Maximilian Knoll, David Kaul
-
Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma J Neurooncol. (IF 3.9) Pub Date : 2024-02-19 Phioanh Leia Nghiemphu, Jeremie Vitte, Eva Dombi, Thien Nguyen, Naveed Wagle, Akira Ishiyama, Ali R. Sepahdari, David Cachia, Brigitte C. Widemann, Derald E. Brackmann, Joni K. Doherty, Michel Kalamarides, Marco Giovannini
-
The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab J Neurooncol. (IF 3.9) Pub Date : 2024-02-19 Pushan Dasgupta, Alexander Ou, Heather Lin, Timothy Gregory, Kristin D. Alfaro-Munoz, Ying Yuan, Vahid Afshar-Khargan, Carlos Kamiya-Matsuoka, Justin F. Rousseau, Nazanin K. Majd
-
Leptomeningeal carcinomatosis and brain metastases in gastroesophageal carcinoma: a real-world analysis of clinical and pathologic characteristics and outcomes J Neurooncol. (IF 3.9) Pub Date : 2024-02-19 Thais Baccili Cury Megid, Zeynep Baskurt, Lucy X. Ma, Carly C. Barron, Abdul Farooq, Marie Phillipe Saltiel, Xin Wang, Yvonne Bach, Hiroko Ayoama, Raymond W. Jang, Eric Chen, Patrick Veit-Haibach, Ben Wang, Sangeetha Kalimuthu, James Cotton, Rebecca Wong, Aruz Mesci, Elena Elimova
-
Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response J Neurooncol. (IF 3.9) Pub Date : 2024-02-19 Samuel A. Bobholz, Alisha Hoefs, Jordyn Hamburger, Allison K. Lowman, Aleksandra Winiarz, Savannah R. Duenweg, Fitzgerald Kyereme, Jennifer Connelly, Dylan Coss, Max Krucoff, Anjishnu Banerjee, Peter S. LaViolette
-
Ki-67 labeling index predicts tumor progression patterns and survival in patients with atypical meningiomas following stereotactic radiosurgery J Neurooncol. (IF 3.9) Pub Date : 2024-02-18
Abstract Purpose This study investigated whether Ki-67 labeling index (LI) correlated with clinical outcomes after SRS for atypical meningiomas. Methods This retrospective study examined 39 patients with atypical meningiomas who underwent SRS over a 10-year study period. Ki-67 LI was categorized into 3 groups: low (< 5%), intermediate (5%–10%), and high (> 10%). Local tumor control rates (LCRs), progression-free
-
Stereotactic radiosurgery for intracranial adenoid cystic carcinoma J Neurooncol. (IF 3.9) Pub Date : 2024-02-16 Jason P. Sheehan, Raj Singh, Daniel M. Trifiletti
-
The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma J Neurooncol. (IF 3.9) Pub Date : 2024-02-16 Yukina Shirai, Toshihide Ueno, Shinya Kojima, Hiroshi Ikeuchi, Rina Kitada, Takafumi Koyama, Fumiyuki Takahashi, Kazuhisa Takahashi, Koichi Ichimura, Akihiko Yoshida, Hirokazu Sugino, Hiroyuki Mano, Yoshitaka Narita, Masamichi Takahashi, Shinji Kohsaka
-
Effect of Pneumocystis jirovecii pneumonia prophylaxis on hematologic toxicity in patients receiving chemoradiation for primary brain tumors J Neurooncol. (IF 3.9) Pub Date : 2024-02-16 Lisa M. Arnold, Yoji Hoshina, Hyejung Lee, Howard Colman, Joe Mendez
-
Predictive role of intracranial PD-L1 expression in a real-world cohort of NSCLC patients treated with immune checkpoint inhibition following brain metastasis resection J Neurooncol. (IF 3.9) Pub Date : 2024-02-15 David Wasilewski, Julia Onken, Paul Höricke, Jan Bukatz, Selin Murad, Anton Früh, Zoe Shaked, Martin Misch, Anja Kühl, Oliver Klein, Felix Ehret, David Kaul, Helena Radbruch, David Capper, Peter Vajkoczy, David Horst, Nikolaj Frost, Philip Bischoff
-
The role of spine stereotactic radiosurgery for patients with breast cancer metastases J Neurooncol. (IF 3.9) Pub Date : 2024-02-14 Suchet Taori, Samuel Adida, Anthony Tang, Akshath Rajan, Roberta K. Sefcik, Steven A. Burton, John C. Flickinger, Pascal O. Zinn, Peter C. Gerszten
-
Repeated surgical resections for management of high-grade glioma and its impact on quality of life J Neurooncol. (IF 3.9) Pub Date : 2024-02-13
Abstract Purpose High-grade gliomas (HGG) are aggressive cancers, and their recurrence is inevitable, despite advances in treatment options. While repeated tumor resection has been shown to increase survival rate, its impact on quality of life is not clearly defined. To address this gap, we compared quality of life (QoL) changes in HGG patients who underwent first-time (FTR) versus repeat surgical
-
Imaging predictors of 4q12 amplified and RB1 mutated glioblastoma IDH-wildtype J Neurooncol. (IF 3.9) Pub Date : 2024-02-13 Antonio Dono, Jose Torres, Luis Nunez, Octavio Arevalo, Juan Carlos Rodriguez-Quinteros, Roy F. Riascos, Arash Kamali, Nitin Tandon, Leomar Y. Ballester, Yoshua Esquenazi
-
Diffuse Midline H3K27-Altered Gliomas in the Spinal Cord: A Systematic Review J Neurooncol. (IF 3.9) Pub Date : 2024-02-12 Gina Watanabe, Jennifer Manyu Wong, Bradley Estes, Mohammad Faizan Khan, Christian Ogasawara, Giuseppe E. Umana, Allan R. Martin, Orin Bloch, Paolo Palmisciano
-
The importance of considering competing risks in recurrence analysis of intracranial meningioma J Neurooncol. (IF 3.9) Pub Date : 2024-02-10 Christian Mirian, Lasse Rehné Jensen, Tareq A. Juratli, Andrea Daniela Maier, Sverre H. Torp, Helen A. Shih, Ramin A. Morshed, Jacob S. Young, Stephen T. Magill, Luca Bertero, Walter Stummer, Dorothee Cäcilia Spille, Benjamin Brokinkel, Soichi Oya, Satoru Miyawaki, Nobuhito Saito, Martin Proescholdt, Yasuhiro Kuroi, Konstantinos Gousias, Matthias Simon, Jennifer Moliterno, Ricardo Prat-Acin, Stéphane
-
Incidence and imaging characteristics of difficult to detect retrospectively identified brain metastases in patients receiving repeat courses of stereotactic radiosurgery J Neurooncol. (IF 3.9) Pub Date : 2024-02-10
Abstract Purpose During stereotactic radiosurgery (SRS) planning for brain metastases (BM), brain MRIs are reviewed to select appropriate targets based on radiographic characteristics. Some BM are difficult to detect and/or definitively identify and may go untreated initially, only to become apparent on future imaging. We hypothesized that in patients receiving multiple courses of SRS, reviewing the
-
Repeat surgery of recurrent glioma for molecularly informed treatment in the age of precision oncology: A risk–benefit analysis J Neurooncol. (IF 3.9) Pub Date : 2024-02-09 Obada T. Alhalabi, Philip Dao Trong, Manuel Kaes, Martin Jakobs, Tobias Kessler, Hannah Oehler, Laila König, Tanja Eichkorn, Felix Sahm, Jürgen Debus, Andreas von Deimling, Wolfgang Wick, Antje Wick, Sandro M. Krieg, Andreas W. Unterberg, Christine Jungk
-
Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas J Neurooncol. (IF 3.9) Pub Date : 2024-02-07 Naureen Keric, Harald Krenzlin, Darius Kalasauskas, Christian F. Freyschlag, Oliver Schnell, Martin Misch, Christian von der Brelie, Jens Gempt, Aleksandrs Krigers, Arthur Wagner, Felipa Lange, Dorothee Mielke, Clemens Sommer, Marc A. Brockmann, Bernhard Meyer, Veit Rohde, Peter Vajkoczy, Jürgen Beck, Claudius Thomé, Florian Ringel
-
Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment J Neurooncol. (IF 3.9) Pub Date : 2024-02-07 Itamar Averbuch, Roi Tschernichovsky, Shlomit Yust-Katz, Ofer Rotem, Dror Limon, Noga Kurman, Oded Icht, Daniel Reinhorn, Mor Moskovitz, Ekaterina Hanovich, Alexandra Benouaich-Amiel, Tali Siegal, Alona Zer, Omer Gal
-
A systematic review of the impact of brain tumours on risk of motor vehicle crashes J Neurooncol. (IF 3.9) Pub Date : 2024-02-06 Sophie Tran, Adam Lapidus, Andrew Neal, Katherine B. Peters, Lucy Gately, Malaka Ameratunga
-
Whole-exome sequencing reveals genetic variants that may play a role in neurocytomas J Neurooncol. (IF 3.9) Pub Date : 2024-02-06
Abstract Objectives Neurocytomas (NCs) are rare intracranial tumors that can often be surgically resected. However, disease course is unpredictable in many patients and medical therapies are lacking. We have used whole exome sequencing to explore the molecular etiology for neurocytoma and assist in target identification to develop novel therapeutic interventions. Methods We used whole exome sequencing
-
Adverse radiation effect versus tumor progression following stereotactic radiosurgery for brain metastases: Implications of radiologic uncertainty J Neurooncol. (IF 3.9) Pub Date : 2024-02-05 Mia Salans, Lisa Ni, Olivier Morin, Benjamin Ziemer, Dante P. I. Capaldi, David R. Raleigh, Harish N. Vasudevan, Jessica Chew, Jean Nakamura, Penny K. Sneed, Lauren Boreta, Javier E. Villanueva-Meyer, Philip Theodosopoulos, Steve Braunstein
-
Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery J Neurooncol. (IF 3.9) Pub Date : 2024-02-03 Joseph D. Tang, Matthew N. Mills, Justyn Nakashima, Ammoren E. Dohm, Nikhil I. Khushalani, Peter A. Forsyth, Michael A. Vogelbaum, Evan J. Wuthrick, Hsiang-Hsuan M. Yu, Daniel E. Oliver, James K. C. Liu, Kamran A. Ahmed
-
The relationship between pathological brain activity and functional network connectivity in glioma patients J Neurooncol. (IF 3.9) Pub Date : 2024-02-03 Mona L. M. Zimmermann, Lucas C. Breedt, Eduarda G. Z. Centeno, Jaap C. Reijneveld, Fernando A. N. Santos, Cornelis J. Stam, Marike R. van Lingen, Menno M. Schoonheim, Arjan Hillebrand, Linda Douw
-
Utility of contrast-enhanced MRI radiomics features combined with clinical indicators for predicting induction chemotherapy response in primary central nervous system lymphoma J Neurooncol. (IF 3.9) Pub Date : 2024-02-03 Xiaochen Wang, Litao Zhao, Sihui Wang, Xuening Zhao, Lingxu Chen, Xuefei Sun, Yuanbo Liu, Jiangang Liu, Shengjun Sun
-
Two is better than one: longitudinal detection and volumetric evaluation of brain metastases after Stereotactic Radiosurgery with a deep learning pipeline J Neurooncol. (IF 3.9) Pub Date : 2024-02-01 Yonny Hammer, Wenad Najjar, Lea Kahanov, Leo Joskowicz, Yigal Shoshan
-
Evaluating contouring accuracy and dosimetry impact of current MRI-guided adaptive radiation therapy for brain metastases: a retrospective study J Neurooncol. (IF 3.9) Pub Date : 2024-02-01 Bin Wang, Yimei Liu, Jun Zhang, Shaohan Yin, Biaoshui Liu, Shouliang Ding, Bo Qiu, Xiaowu Deng
-
The effectiveness and safety of proton beam radiation therapy in children and young adults with Central Nervous System (CNS) tumours: a systematic review J Neurooncol. (IF 3.9) Pub Date : 2024-01-31 Jayne S. Wilson, Caroline Main, Nicky Thorp, Roger E. Taylor, Saimma Majothi, Pamela R. Kearns, Martin English, Madhumita Dandapani, Robert Phillips, Keith Wheatley, Barry Pizer
-
Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: a systematic review J Neurooncol. (IF 3.9) Pub Date : 2024-01-31 Eric Singh, Muhammet Enes Gurses, Meredith C. Costello, Victor M. Lu, Lekhaj Daggubati, Ricardo J. Komotar, Michael E. Ivan, Ashish H. Shah
-
An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma J Neurooncol. (IF 3.9) Pub Date : 2024-01-31 Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Yohei Yamamoto, Ryotaro Imai, Yuki Kuranari, Kyoichi Tohmoto, Yuzuru Hasegawa, Yasuharu Akasaki, Yuichi Murayama, Keisuke Miyake, Hikaru Sasaki
-
Clinical and molecular determinants of bleeding-related adverse outcomes in high-grade glioma J Neurooncol. (IF 3.9) Pub Date : 2024-01-29 Pushan Dasgupta, Justin F. Rousseau
Purpose Cancer is an independent risk factor for the development of venous thromboembolism (VTE). However, patients with high-grade glioma (HGG) including glioblastoma (GBM) are at a particularly high risk of VTE with an incidence up to 20–30% per year. Patients are often placed on anticoagulation if they are found to have VTE. However, patients with primary brain tumors such as HGG are at increased
-
Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting J Neurooncol. (IF 3.9) Pub Date : 2024-01-29
Abstract Purpose Next generation sequencing (NGS) is an important tool used in clinical practice to obtain the required molecular information for accurate diagnostics of high-grade adult-type diffuse glioma (HGG). Since individual centers use either in-house produced or standardized panels, interlaboratory variation could play a role in the practice of HGG diagnosis and treatment. This study aimed
-
Iron-based biomarkers for personalizing pharmacological ascorbate therapy in glioblastoma: insights from a phase 2 clinical trial J Neurooncol. (IF 3.9) Pub Date : 2024-01-29 M. S. Petronek, K. L. Bodeker, C. Y. Lee, N. Teferi, K. L. Eschbacher, K. A. Jones, B. T. Loeffler, B. J. Smith, J. M. Buatti, V. A. Magnotta, B. G. Allen
-
GammaTile® (GT) as a brachytherapy platform for rapidly proliferating glioblastomas: from case series to clinical trials J Neurooncol. (IF 3.9) Pub Date : 2024-01-28 Anudeep Yekula, Dominic J. Gessler, Clara Ferreira, Rena Shah, Margaret Reynolds, Kathryn Dusenbery, Clark C. Chen
-
Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma J Neurooncol. (IF 3.9) Pub Date : 2024-01-26 Maria F. Gonzalez-Aponte, Anna R. Damato, Laura Lucía Trebucq, Tatiana Simon, Sandra P. Cárdenas-García, Kevin Cho, Gary J. Patti, Diego A. Golombek, Juan José Chiesa, Joshua B. Rubin, Erik D. Herzog
-
CDKN2A/B deletion in IDH-mutant astrocytomas: An evaluation by Fluorescence in-situ hybridization J Neurooncol. (IF 3.9) Pub Date : 2024-01-24
Abstract Introduction CDKN2A/B homozygous deletion is one of the defining features of grade 4 in IDH-mutant astrocytic tumours. Aim To evaluate CDKN2A/B-deletion in IDH-mutant astrocytic tumours and its clinicopathological impact. Materials and methods CDKN2A/B-deletion was evaluated by Fluorescence in-situ hybridisation (FISH) and interpreted by two recently accepted methods. Results Eighty-three
-
MRI Treatment Response Assessment Maps (TRAMs) for differentiating recurrent glioblastoma from radiation necrosis J Neurooncol. (IF 3.9) Pub Date : 2024-01-23
Abstract Background MRI treatment response assessment maps (TRAMs) were introduced to distinguish recurrent malignant glioma from therapy related changes. TRAMs are calculated with two contrast-enhanced T1-weighted sequences and reflect the “late” wash-out (or contrast clearance) and wash-in of gadolinium. Vital tumor cells are assumed to produce a wash-out because of their high turnover rate and the